JNK2 Protein (AA 101-424) (His tag)

N° du produit ABIN7505293

Détail du produit

Antigène: JNK2 (MAPK9) (Mitogen-Activated Protein Kinase 9 (MAPK9))

Type de proteíne: Recombinant

Attributs du protein: AA 101-424

Origine: Humain

Source: Escherichia coli (E. coli)

Purification/Conjugué: Cette JNK2 protéine est marqué à la His tag.

Séquence: Phe 101-Arg 424

Attributs du produit: A DNA sequence encoding the Human MAPK9 protein (P45984) (Phe 101-Arg 424) was expressed with a N-His&C-His tag.

Pureté: > 95 % as determined by reducing SDS-PAGE.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween80 are added as protectants before lyophilization.

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Date de péremption: 12 months

Détail du antigène

Antigène: JNK2 (MAPK9) (Mitogen-Activated Protein Kinase 9 (MAPK9))

Autre désignation: MAPK9 (MAPK9 Produits)

Synonymes: MAPK9 Protein, JNK-55 Protein, JNK2 Protein, JNK2A Protein, JNK2ALPHA Protein, JNK2B Protein, JNK2BETA Protein, PRKM9 Protein, SAPK Protein, SAPK1a Protein, p54a Protein, p54aSAPK Protein, AI851083 Protein, Prkm9 Protein, JNK2-ALPHA1 Protein, MAP kinase 9 Protein, mitogen-activated protein kinase 9 Protein, MAP kinase 9 Protein, MAPK9 Protein, Mapk9 Protein, MPK9 Protein

Sujet:

Abbreviation: MAPK9

Target Synonym: JNK-55,JNK2,JNK2A,JNK2ALPHA,JNK2B,JNK2BETA,p54a,p54aSAPK,PRKM9,SAPK,SAPK1a

Background: Mitogen-activated protein kinase 9 (MAPK9), also well known as c-Jun N-terminal kinase (JNK2), is a member of MAP kinase subfamily belonging to the protein kinase superfamily. The crystal structure of human JNK2 complexed with an indazole inhibitor by applying a high-throughput protein engineering and surface-site mutagenesis approach. A novel conformation of the activation loop is observed, which is not compatible with its phosphorylation by upstream kinases. This activation inhibitory conformation of JNK2 is stabilized by the MAP kinase insert that interacts with the activation loop in an induced-fit manner. It suggest that the MAP kinase insert of JNK2 plays a role in the regulation of JNK2 activation, possibly by interacting with intracellular binding partners. JNK2 deficiency leads to reduced c-Jun degradation, thereby augmenting c-Jun levels and cellular proliferation, and suggests that JNK2 is a negative regulator of cellular proliferation in multiple cell types. JNK2 blocks the ubiquitination of tumor suppressor p53, and thus increases the stability of p53 in nonstressed cells. JNK2 negatively regulates antigen-specific CD8+ T cell expansion and effector function, and thus selectively blocking JNK2 in CD8+ T cells may potentially enhance anti-tumor immune response. Lack of JNK2 expression was associated with higher tumor aneuploidy and reduced DNA damage response. Additionally,the JNK2 protein could be a novel therapeutic target in dry eye disease, and may provide a novel target for prevention of vascular disease and atherosclerosis.

Poids moléculaire:

Calculated MW: 35.53 kDa

Observed MW: 41 kDa

UniProt: P45984

Pathways: Signalisation MAPK, Signalisation WNT, Signalisation TLR, Fc-epsilon Receptor Signaling Pathway, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Positive Regulation of Endopeptidase Activity, Hepatitis C, Toll-Like Receptors Cascades, BCR Signaling, S100 Proteins